Literature DB >> 11206040

Mycophenolic acid plasma concentrations: influence of comedication.

L Pou1, M Brunet, C Cantarell, E Vidal, F Oppenheimer, V Monforte, J Vilardell, A Roman, J Martorell, L Capdevila.   

Abstract

Mycophenolate mofetil (MMF) in combination with cyclosporine (CsA) or Tacrolimus (TAC) has been show to be a potent immunosuppressive agent. The authors assessed the mycophenolic acid (MPA) plasma levels achieved in clinical practice and evaluated the effect of concomitant administration of CsA and TAC . One hundred forty transplant patients (kidney: 120 and lung: 20) received a triple immunosuppression regimen of CsA or TAC, prednisone and MMF. Twenty-two renal transplant patients received double therapy with MMF and prednisone. There was no correlation between MMF dose and MPA trough concentrations (r = -0.0657). The medians (range) of the MPA dose-to-concentration ratio (D/C) in the CsA and TAC groups were 0.90 (0.11-8.33) and 0.56 (0.11-14.3), respectively (p < 0.0001). According to the post transplant period (1-3, 4-6 and >6 months), D/C values were significantly lower in patients receiving MMF and TAC than those receiving MMF and CsA in all three periods. MPA levels in patients treated with MMF and CsA were significantly lower than those obtained in double therapy. The D/C ratio in CsA-treated patients, increased significantly (p = 0.0005) when CsA level increased. There was no relationship between D/C ratio and TAC blood concentrations. These results suggest that CsA exerts an influence on MPA trough levels, although further work is required to characterize the mechanism of interaction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11206040     DOI: 10.1097/00007691-200102000-00007

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  18 in total

1.  Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis.

Authors:  B C Ferslew; C K Johnston; E Tsakalozou; A S Bridges; M F Paine; W Jia; P W Stewart; A S Barritt; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2015-03-15       Impact factor: 6.875

Review 2.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 3.  Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part II.

Authors:  Caroline Monchaud; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 4.  Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I.

Authors:  Caroline Monchaud; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

5.  Role of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat.

Authors:  Brian C Ferslew; Kathleen Köck; Arlene S Bridges; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2014-06-23       Impact factor: 3.922

6.  Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients.

Authors:  Dirk R Kuypers; Henrik Ekberg; Josep Grinyó; Björn Nashan; Flavio Vincenti; Paul Snell; Richard D Mamelok; Rene M Bouw
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Population Pharmacokinetics of Mycophenolic Acid: An Update.

Authors:  Tony K L Kiang; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 6.447

Review 8.  To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription.

Authors:  Guido Filler; Nathalie Lepage
Journal:  Pediatr Nephrol       Date:  2004-07-15       Impact factor: 3.714

9.  Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure.

Authors:  Krista L Lentine; Lisa A Rocca Rey; Swathy Kolli; Giuliana Bacchi; Mark A Schnitzler; Kevin C Abbott; Huiling Xiao; Daniel C Brennan
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 8.237

10.  Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.

Authors:  Paul J Martin; Barry E Storer; Scott D Rowley; Mary E D Flowers; Stephanie J Lee; Paul A Carpenter; John R Wingard; Paul J Shaughnessy; Marcel P DeVetten; Madan Jagasia; Joseph W Fay; Koen van Besien; Vikas Gupta; Carrie Kitko; Laura J Johnston; Richard T Maziarz; Mukta Arora; Pamala A Jacobson; Daniel Weisdorf
Journal:  Blood       Date:  2009-03-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.